

Press release

Oxford BioMedica plc Annual General Meeting

London, UK – 29 May 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:

- Resolution 10: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares;
- Resolution 11: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment; and
- Resolution 12: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.

Certified copies of the document setting out the above resolutions passed at the 2018 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: <http://www.morningstar.co.uk/uk/NSM>.

The results of the proxy voting in advance of the meeting are shown below. On the Record Date (24 May 2018) there were 3,285,053,283 1p ordinary shares in issue, each carrying one vote per share.

Resolution	Votes For	Votes at Chairman's Discretion	Votes at other proxy Discretion	Votes Against	Votes Withheld	Total votes cast	Result
Ordinary resolutions							
1	1,988,588,475	582,120	5,741,189	233,441	85,853	1,995,231,078	Passed
2	1,982,688,012	657,354	5,741,189	4,411,157	1,733,366	1,995,231,078	Passed
3	1,923,486,721	811,240	5,741,189	56,288,698	8,903,541	1,995,231,389	Passed
4	1,988,021,008	669,140	5,741,189	494,021	305,721	1,995,231,079	Passed
5	1,988,311,289	655,920	5,741,189	216,678	306,314	1,995,231,390	Passed
6	1,988,029,653	655,920	5,741,189	622,025	182,292	1,995,231,079	Passed
7	1,988,368,406	674,159	5,741,189	178,737	268,588	1,995,231,079	Passed
8	1,988,584,716	657,182	5,741,189	153,238	95,065	1,995,231,390	Passed

9	1,986,683,108	641,653	5,741,189	767,858	1,397,270	1,995,231,078	Passed
Special resolutions							
10	1,986,880,927	629,431	5,741,189	1,134,133	845,710	1,995,231,390	Passed
11	1,986,323,670	624,811	5,741,189	1,687,542	854,177	1,995,231,389	Passed
12	1,971,075,702	624,811	5,741,189	17,667,961	121,727	1,995,231,390	Passed

- Ends -

For further information, please contact:

Oxford BioMedica plc:

John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer

Tel: +44 (0)1865 783 000

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton

Tel: +44 (0)20 3709 5700

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop *in vivo* and *ex vivo* products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.